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Abstract
Myofibroblasts are key fibrogenic cells responsible for excessive extracellular matrix synthesis characterizing the fibrotic lesion. In liver fibrosis,
myofibroblasts derive either from activation of hepatic stellate cells (HSC) and portal fibroblasts (PF), or from the activation of fibroblasts that
originate from ductular epithelial cells undergoing epithelial–mesenchymal transition. Ductular cells can also indirectly promote myofibroblast
generation by activating TGF-b, the main fibrogenic growth factor, through avb6 integrin. In addition, after liver injury, liver sinusoidal cells can
lose their ability to maintain HSC quiescence, thus favouring HSC differentiation towards myofibroblasts. The amniotic membrane and epithelial
cells (hAEC) derived thereof have been shown to decrease hepatic myofibroblast levels in rodents with liver fibrosis. In this study, in a rat model
of liver fibrosis, we investigated the effects of hAEC on resident hepatic cells contributing to myofibroblast generation. Our data show that hAEC
reduce myofibroblast numbers with a consequent reduction in fibronectin and collagen deposition. Interestingly, we show that hAEC strongly
act on specific myofibroblast precursors. Specifically, hAEC reduce the activation of PF rather than HSC. In addition, hAEC target reactive ductu-
lar cells by inhibiting their proliferation and avb6 integrin expression, with a consequent decrease in TGF-b activation. Moreover, hAEC counter-
act the transition of ductular cells towards fibroblasts, while it does not affect injury-induced and fibrosis-promoting sinusoidal alterations. In
conclusion, among the emerging therapeutic applications of hAEC in liver diseases, their specific action on PF and ductular cells strongly sug-
gests their application in liver injuries involving the expansion and activation of the portal compartment.
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Introduction
Liver fibrosis, consequent to chronic liver injuries such as viral infec-
tions, alcohol and drug intoxications, metabolic disorders and
cholestasis, is a major cause of morbidity and mortality worldwide
[1]. Liver fibrogenesis is a complex and dynamic process involving a
heterogeneous population of fibrogenic hepatic cells. Among these,
myofibroblasts are the key cells responsible for the excessive extra-
cellular matrix (ECM) synthesis characterizing the fibrotic lesion, and
their increased number correlates with the severity of liver fibrosis
[2]. Myofibroblasts derive from the activation of resident
mesenchymal populations: HSC and PF (Fig. 1), or from epithelial
(ductular epithelial cells) or endothelial (liver sinusoidal endothelial
cells: LSEC) resident cells that directly or indirectly contribute to
myofibroblast generation (Fig. 1).
Investigations mostly performed in rat [3–5] and mouse models
[6, 7] of hepatic fibrosis demonstrated that HSC and PF activation
towards myofibroblasts is consequent to a complex network of auto-
crine/paracrine fibrogenic signals, generated from an injury event,
which promote up-regulation of ECM proteins (e.g. fibronectin and
collagen 1A1) and a-smooth muscle actin (a-SMA), conferring myofi-
broblasts with the ability to migrate to the site of injury [6, 8].
In the animal model of common bile duct ligation (BDL) applied in
this study, which mimics obstruction to bile flow, such as that found
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in primary biliary cirrhosis and primary sclerosing cholangitis, PF play
an important role in early ECM deposition around portal tracts [3–6]
and trigger HSC activation and migration (from the space of Disse to
the injured area); HSC are instead crucial for the subsequent progres-
sion of the fibrotic lesion [6].
Furthermore, growing experimental evidence has shown that duc-
tular epithelial cells (Fig. 1) also contribute to biliary fibrosis [9]. In
the early stage of biliary liver injury, ductular epithelial cells give rise
to a composite reaction named ‘ductular reaction’ characterized by a
marked expansion of the ductular compartment which adopts an
inflammatory phenotype. Reactive ductular epithelial cells can
undergo epithelial-to-mesenchymal transition (EMT), a dynamic pro-
cess in which ductular cells lose their epithelial phenotype and gradu-
ally acquire a fibroblast and motile phenotype, with the potential to
migrate out of the epithelial lining into the adjacent periportal stroma
and transdifferentiate to myofibroblasts [9, 10]. Reactive ductular
epithelial cells can also indirectly promote myofibroblast generation
by secreting several pro-inflammatory and chemotactic cytokines
(such as IL-6 and MCP-1) and growth factors (VEGF, PDGF, TGF-b2,
CTGF), which mediate the recruitment and activation of inflammatory
and mesenchymal (HSC and PF) cells [11]. Importantly, reactive duc-
tular cells can activate TGF-b, the key fibrogenic growth factor which
drives fibroblast activation and ECM synthesis, through the expres-
sion of avb6 integrin on their own cell membrane [12].
Finally, LSEC (Fig. 1) represent another liver cell population with a
role in the fibrogenic process [13]. These cells are specific endothelial
cells which, containing fenestrae and lacking the basement mem-
brane, allow an efficient exchange of metabolites and oxygen between
the blood and hepatocytes. Under normal conditions, they produce
paracrine factors crucial to maintain HSC inside the space of Disse
and under quiescent status [14]. Under cholestatic injury, LSEC mor-
phology and functionality are altered, they lose their characteristic
fenestrae (process named ‘defenestration’) and importantly their abil-
ity in preserving HSC quiescence [14].
The study of the main fibrogenic cells contributing to liver injury
and the mechanism(s) of activation in different fibrotic injury etiolo-
gies could provide new important targets to develop an effective
antifibrotic therapy. The therapeutic options now under investigation
include molecules that suppress/reduce reactive oxygen species
(such as vitamin E), inflammatory mediators (anti-TNF-a, anti-IL-6
compounds) or that block angiotensin II (such as losartan), all of
which are involved in HSC activation [15].
Among the proposed antifibrotic approaches, cell-based thera-
pies have been shown to reduce liver fibrosis in different animal
models. We and others have demonstrated that the amniotic mem-
brane and cells derived thereof, namely human amniotic mesenchy-
mal stromal cells (hAMSC) and amniotic epithelial cells (hAEC),
decrease hepatic fibrosis induced by BDL [16–18] and by CCl4
intoxication [19–22].
Until now studies have been focused on the ability of amniotic
cells either to favour hepatocyte proliferation/regeneration [20, 23] or
to counteract fibrosis progression by modulating the inflammatory
environment through the reduction in inflammatory cytokines [19]
and the recruitment [21], activation [22] and differentiation [21] of
hepatic macrophages.
However, studies aimed to examine the activity of hAEC on the
resident hepatic cells that contribute to myofibroblast generation are
lacking. Therefore, the aim of this study was to investigate the effects
of hAEC on HSC, PF, epithelial ductular cells and LSEC in order to
identify the specific target of hAEC treatment.
Fig. 1 Liver structure and hepatic fibro-
genic cells. The liver consists of lobules,
representing the hepatic functional unit
(panel A). Each lobule is intersected by a
central vein (CV), from which hepatocyte
cords radiate towards portal triads (PT)
containing three different structures: bile
ducts (BD), hepatic artery (HA) and portal
vein (PV). Hepatocyte cords are separated
by sinusoids, blood vessels lined by spe-
cialized fenestrated endothelial cells (liver
sinusoidal cells). Hepatic stellate cells
(HSC) are located in the space of Disse,
and portal fibroblasts (PF) in the portal
triad areas. Under injury conditions, both
HSC and PF can be activated to myofi-
broblasts (ECM-producing cells). Ductular
epithelial cells, another cell type involved
during liver injury, line the bile ducts.
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Materials and methods
Ethics statements
Human term placentas were collected after obtaining written informed
consent according to the guidelines of the Ethical Committee of the Pro-
vince of Brescia (Comitato Etico Provinciale).
Animal experiments were carried out in accordance with the guide-
lines established by the Italian law DL 26/2014 on the accommoda-
tion and care of animals used for scientific purposes. The
experimental protocol was approved by Italian Ministry of Health
(authorization n. 427/2015 PR) and by the Committee on the Ethics
of Animal Experiments of the University of Milano (n. 105/14, 9/12/
2014).
All animals received humane care according to the criteria outlined in
the ‘Guide for the Care and Use of Laboratory Animals’ prepared by the
National Academy of Sciences and published by the National Institutes
of Health (NIH publication 86-23 revised 1985).
hAEC isolation
hAEC were isolated from term placentas (n = 5) as previously described
[24]. Briefly, the amnion was detached from chorion and washed in
PBS (Sigma-Aldrich, St Louis, MO, USA) supplemented with 100 U/ml
penicillin (Lonza, Basel, Switzerland) and 100 lg/ml streptomycin
(Sigma-Aldrich). Amnion fragments ( ̴ 15 9 15 cm) were incubated for
10 min. at 37°C in PBS containing 0.5 mM EDTA and P/S, and then in
1X trypsin/EDTA solution (Sigma-Aldrich) for 5 min. at 37°C. After dis-
carding debris, the fragments were again incubated (10 min. at 37°C)
in fresh trypsin/EDTA solution and, after washing in PBS, were once
more digested in trypsin/EDTA. The cells from the second and third
digestions were pooled and centrifuged at 3009 g for 10 min. Cell sus-
pensions were then filtered through a 70-lm cell strainer (BD Bio-
sciences, San Jose, CA, USA), centrifuged and counted. Isolated cells
were cryopreserved in 10% DMSO (Sigma-Aldrich) supplemented with
90% FBS until use.
hAEC batches with cells over 95% positive for CD324 and CD166,
and negative for CD44, CD105 and CD45 were used. Cell viability after
thawing was always higher than 85%.
Biliary fibrosis induction and animal treatment
All experimental procedures were performed on anaesthetized animals.
Biliary fibrosis was induced by BDL in female Wistar rats weighing
220–250 g (Charles River Laboratories, Calco, Italy), as previously
described [16, 18]. Briefly, anaesthesia was induced with 5% isoflurane
(IsoFlo Abbott Laboratories, Maidenhead, UK) and maintained at 2.5%
during the surgical procedure. Before BDL, 4 mg/Kg Carprofen
(Rimadyl, Pfizer, Milano, Italy) and 5 mg/Kg Enrofloxacin (Baytril,
Bayer, Milano, Italy) were administered by subcutaneous injection to
decrease pain and prevent infection. The common bile duct was
exposed through a whole thickness laparoscopic midline incision, then
ligated and sectioned to produce a permanent biliary obstruction. After
BDL, 5 mg/kg vitamin K (Fitomenadione, Konakion, Roche Products
Limited, Welwyn Garden City, UK) was administered weekly to reduce
haemorrhagic diathesis.
Immediately after BDL, animals were randomly treated through intra-
tail vein (iv) injections, either with 400 ll PBS (BDL + PBS group) or
with 3 9 106 hAEC in 400 ll PBS (BDL + hAEC group). All animals
were killed 6 weeks post-surgery with an excess of isoflurane followed
by puncture of the right ventricle and exsanguination.
Serum bilirubin
Total bilirubin concentrations were determined in serum collected from
animals 7 days after BDL, by the diazo method using Bilirubina totale,
metodo colorimetrico (DMSO) Kit (Giesse Diagnostic snc, Roma, Italy)
according to the manufacturer’s recommendations.
Liver histological examination
At sacrifice, a portion of the hepatic median lobe from each animal was
immediately fixed in 4% formalin for 48 hrs and paraffin-embedded.
To assess the degree of liver fibrosis, 4-lm-thick sections were
stained with haematoxylin/eosin and Goldner’s modified Masson tri-
chrome, according to the manufacturer’s instructions (BiOptica,
Milano, Italy). Histological grading of liver fibrosis was evaluated on
microscopic fields centred on hepatic lobules, under a bright field
microscope (Olympus BX41, Tokyo, Japan) at 1009 magnification, by
the semiquantitative Knodell’s scoring system [25] performed by a
pathologist kept blinded of the treatment applied. This score system
allows a staging of liver fibrotic lesions considering the progressive
expansion of the collagen deposits, from portal regions to gradually
involving the interstitial parenchyma and finally resulting in liver
remodelling [16, 17]. The average of the score taken from 10 to 12
non-overlapping random fields per section was used to generate a sin-
gle score for each animal.
To evaluate the extent of liver collagen deposition, sections were
incubated in PicroSirius Red (PSR; Sigma-Aldrich; Direct Red 80, 0.1%
wt/vol in saturated picric acid) for 80 min. and washed for 3 min. in
tap water. Twelve non-overlapping fields were acquired (2009 magnifi-
cation), images digitized and PSR-positive area measured by computer-
assisted morphometric analysis using FiJi software (https://imagej.nih.
gov/ij).
Immunohistochemistry
Serial liver sections of each specimen were immuno-stained for
a-SMA (1:600; Clone 1A4, Dako, Glostrup, Denmark); fibronectin
(1:100, clone 10/Fibronectin, BD Transduction Laboratories, Franklin
Lakes, NJ, USA); desmin (1:1,000, Gene-Tex, Aachen, Germany); colla-
gen 15A1 (1:100, clone N20, Santa Cruz Biotechnology, Dallas, Tx,
USA); cytokeratin 19 (CK19) (1:100, clone-b170, Leica Biosystems,
Newcastle, UK); avb6 integrin (1:150, Bioss Inc. Woburn, MA, USA);
S100A4, also called fibroblast-specific protein-1 (FSP-1) (1:300, Dako);
phosphorylated Smad 2/3 (p-Smad2/3) (1:200, Santa Cruz Biotechnol-
ogy); CD32b (1:500, Sino Biological, Beijing, China) and CD34 (1:50,
Bioss Inc.).
Briefly, dewaxing and antigen retrieval was performed at 98°C for
20–30 min. in a citrate buffer solution pH 6 (BiOptica); a further diges-
tion of 10 min. in trypsin solution (Invitrogen Corporation, Frederick,
MD, USA) at 37°C was necessary for CK19 detection.
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Endogenous peroxidase activity was quenched by 10-min. incubation
with Dako REAL Peroxidase-Blocking Solution (Dako), and unspecific
labelling was minimized by a 30-min. incubation with 2.5% normal
horse serum (ImmPRESS reagent kit, Vector Laboratories, Burlingame,
CA, USA) or with 10% normal goat serum (Invitrogen Corporation).
Sections, incubated overnight at 4°C with one of the primary antibod-
ies, were then washed and incubated with an horseradish peroxidase
(HRP)-conjugated secondary antibody (ImmPRESS reagent kit, rat
absorbed, Vector Laboratories) or with a biotinylated secondary anti-
body (Vector Laboratories) (fibronectin, collagen 15A1, p-Smad2/3 and
CD32b). In this last case, antibody binding was detected by Strepta-
vidin-HRP (Vector Laboratories). Diaminobenzidine (ImmPACT DAB,
Vector Laboratories) was used as the chromogen.
Slides were counterstained with haematoxylin and mounted. Substi-
tution of primary antibody with an irrelevant IgG served as a negative
control.
For each marker, 10–18 single images at 2009 magnification were
taken from each tissue section with a digital camera (Olympus Camedia
C-4040 ZOOM), yielding homogeneous 24 bit colour images with a
1024 9 768 pixel size and 200 dpi resolution. The % of area positive
for each marker was calculated by computer-assisted morphometric
analysis using FiJi software (https://imagej.nih.gov/ij).
Polymerase chain reaction
Total RNA was extracted from snap-frozen portions of the hepatic med-
ian lobe using EZ1 RNA Universal Tissue Kit (Qiagen, Hilden, Germany)
following manufacturer’s instructions. One hundred nanograms (2 ll) of
total RNA was retrotranscribed to cDNA using the ImProm-IITM Rev-
erseTranscription System (Promega, Madison, WI, USA) and amplified
by polymerase chain reaction (PCR) in a final volume of 50 ll, using
Go Taq Polymerase (Promega). The nucleotide sequences of primers
used in the PCR are listed in Table 1. Samples were denatured at 95°C
for 10 min., then exposed to 25 (collagen1A1)/28 (CK19)/30 (desmin;
fibronectin; a-SMA; S100A4) or 32 (collagen15A1; avb6 integrin) cycles
of denaturation (at 95°C for 30 sec.), annealing at 54°C (fibronectin;
avb6 integrin)/56°C (collagen 15A1; a-SMA; CK19; S100A4) or 58°C
(collagen 1A1; desmin) for 30 sec., and elongation (72°C for 60 sec.)
followed by a final elongation at 72°C for 7 min.
Housekeeping genes (b-actin or 18S rRNA) were used as internal
controls to calculate relative quantification of target gene expression.
Target and housekeeping genes were amplified in the same reaction.
The amplified PCR products were stained with ethidium bromide on
a 1.5% agarose gel and visualized by UV light and photographed using
UV transilluminator GelDoc 2000 system (Bio-Rad Laboratories S.r.l.,
Segrate, Italy). Gels were analysed by ImageJ software (http://rsb.info.
nih.gov/ij/docs/menus/analyze.html#gels) to calculate the intensity val-
ues of strips.
Statistical analysis
Data are expressed as median values and the relative interquartile range
(IQR). Differences between experimental groups (PBS and hAEC
groups) were assessed by nonparametric Mann–Whitney test. A P
value < 0.05 was considered statistically significant. Statistical analysis
was performed with GraphPad Prism 6 Software (GraphPad Software,
San Diego, CA, USA).
Results
hAEC treatment reduces extracellular matrix
deposition
Liver fibrosis can be defined as a result of the progressive accumula-
tion and remodelling of the ECM, which disrupts the normal hepatic
architecture.
In this study, liver fibrosis was induced in rats by BDL. The pres-
ence of jaundice (2 days post-ligation) and high serum concentra-
tions of total bilirubin (ranged between 118.3 and 273.1 lmol/l in
BDL-injured animals versus 0.3 and 1.2 lmol/l in non-injured ones)
indicated a successful obstruction.
ECM presence in healthy livers was very low. Fibronectin was
observed within the portal area and around the central vein (the per-
centage of area occupied by fibronectin-positive cells in sections from
healthy livers was between 0.5 and 1.3%); collagen was present in
very low amounts in the periportal area as a thin rim around blood
vessels.
On the other hand, livers extracted from control animals
(BDL + PBS group) 6 weeks after BDL showed a large amount of
ECM. Fibronectin was arranged around biliary ducts and along hepatic
sinusoids (Fig. 2A). Collagen deposits were mainly found around the
biliary ductular structures forming bridging septa which link adjacent
portal areas and infiltrated liver parenchyma connecting portal areas
and the lobule central vein (Fig. 2B).
To evaluate the effects of hAEC treatment, the degree of fibrosis
in livers from control and treated animals was determined by analys-
ing fibronectin deposition, collagen accumulation (through quantita-
tion of collagen-positive area on PSR-stained liver sections) and
collagen distribution in hepatic lobules (through Knodell’s score sys-
tem applied to Masson’s stained liver sections, see Material and
Methods section).
We observed that hAEC treatment significantly decreased fibro-
nectin deposition [from 11.67 (IQR: 8.53) to 6.88 (IQR: 5.82) %
liver-positive area, P < 0.05] (Fig. 2A). It also reduced both colla-
gen accumulation [10.50 (IQR: 5.06) versus 13.47 (IQR: 8.32), %
liver area occupied by PSR-positive staining] (Fig. 2B) and colla-
gen distribution [2.04 (IQR: 1.69) versus 2.50 (IQR: 0.78) score
units in treated and control rats, respectively] (Fig. 2C). These
results were in line with fibronectin and collagen 1A1 mRNA liver
expression (Fig. 2D and E).
hAEC decrease hepatic fibroblast (PF and HSC)
activation
Myofibroblasts are characterized by a contractile phenotype and typi-
cally express a-SMA. In liver sections from healthy rats, a-SMA
expression is very low and limited to the wall of portal vessels. As
expected, in livers from fibrotic rats, a-SMA-positive cells are instead
located also around biliary ducts, thus in the same areas occupied by
fibronectin and collagen deposits. hAEC-treated animals showed a
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significant lower area occupied by myofibroblasts with respect to liv-
ers from control animals [1.22 (IQR: 1.01) versus 2.33 (IQR: 3.06) %
liver-positive area for a-SMA, P < 0.01] (Fig. 3A).
As myofibroblasts can derive from the activation of PF and HSC,
we examined whether hAEC can impact the activation of these cells.
We therefore investigated the phenotype of myofibroblasts arising
from PF activation as collagen 15A1-positive cells [4], and those aris-
ing from HSC activation as desmin-positive cells [6]. We also anal-
ysed collagen 15A1 and desmin mRNA expression in whole liver
extracts.
In liver sections of healthy rats, very rare collagen 15A1-positive
cells were present in the periportal areas. Similarly, desmin staining
was very scant, and rare positive cells (0.5–0.9% of the total section
area) were restricted to arterial walls and along sinusoids.
The presence of these markers increased in BDL-injured rats.
It is noteworthy that hAEC displayed a significant inhibition on
myofibroblasts arising from PF activation [3.32 (IQR: 0.96) versus
4.13 (IQR: 1.11) % collagen 15A1-positive area, P < 0.05] (Fig. 3B).
hAEC-treated animals also showed a reduced number of myofibrob-
lasts deriving from HSC, although this effect was not significant
[2.61 (IQR: 3.07) versus 4.18 (IQR: 2.39) % desmin-positive area in
hAEC-treated and control groups, respectively; P = 0.1203]
(Fig. 3C).
Data collected from PCR analysis were in line with those obtained
from IHC analysis. (Fig. 3A–C).
hAEC reduce the fibrogenic activity of hepatic
ductular epithelial cells
We then addressed the hypothesis that hAEC may reduce myofibrob-
last generation by acting on ductular epithelial cells. In healthy livers,
ductular structures were limited and present only in the portal areas
(in our staining condition, they occupied about 0.6–1.0% of the total
Table 1 Primer sequences for RT-PCR
Genes Primer sequence (50-30) Tm (°C) Size (bp)
a-SMA F: TGCTCCAGCTATGTGTGAAGA 56 325
R: AGGTCGGATGCTCCTCTG
Fibronectin F: CCAGGCACTGACTACAAGAT 54 145
R: CATGATACCAGCAAGGACTT
Desmin F: GACCTAGAGCGCAGAATTGAGT 58 476
R: GCCATCTCATCCTTTAGGTGTC
Collagen 15A1 F: GCCCCCTACTTCATCCTCTC 56 154
R: CAGTACGGACCTCCAGGGTA
Collagen 1A1 F: TGAGCCAGCAGATTGAGAACA 58 120
R: GGGTCGATCCAGTACTCTCCG
S100A4 F: ATACTCAGGCAACGAGGGTG 56 245
R: CTTCCGGGGCTCCTTATC
CK19 F: ACACCAGGCATTGACCTAGC 56 279
R: TCCGTAACGGGCCTCTATCT
avb6 Integrin F: ATCCTGCTCATCGGTGTCG 54 188
R: CTTTGTGCTTCTCCCTGTTTG
Housekeeping genes
b-actin F: GAGAGGGAAATCGTGCGTGAC 452
R: CCCATACCCACCATCACACC
18S rRNA F: GAGCGAAAGCATTTGCCAAG 100
R: GGCATCGTTTATGGTCGGAA
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section area). In response to biliary obstruction, ductular epithelial
cells intensively proliferate and give rise to increased numbers of bil-
iary structures (‘ductular reaction’).
We first assessed whether hAEC treatment could limit the ductular
reaction by detecting CK19-positive cells, a marker which is normally
expressed by ductular epithelial cells (Fig. 4A). hAEC-treated animals
showed a severe and significant decrease in CK19 protein expression
[12.24 (IQR: 2.71) versus 6.47 (IQR: 7.79), P < 0.05] (Fig. 4A) and
mRNA expression [100.8 (IQR: 49.9) versus 38.5 (IQR: 39.8),
P < 0.05] with respect to control animals.
We further investigated whether hAEC could inhibit the possi-
ble transition of ductular epithelial cells towards a fibroblast phe-
notype. For this purpose, we assessed hepatic cells expressing
S100A4 (also called FSP-1), a marker of epithelial–mesenchymal
transition [10, 26]. In livers from fibrotic control animals, the
number of S100A4-positive cells ranged from 52.4 to 87.2 in
each analysed field, most of these cells (more than 50%) were
located in the periductular areas (Fig. 4B–D). Livers from hAEC-
treated animals exhibited a lower number of cells positive for
S100A4 [54.6 (IQR: 42.2) versus 70.7 (IQR: 25.9)] (Fig. 4B). The
treatment did not affect the number of positive cells located in
ductular and parenchymal areas, but rather those close to ductu-
lar structures (periductular cells) (Fig. 4D). In hAEC-treated ani-
mals, there were 28.3 (IQR: 24.4) periductular S100A4-positive
cells/field versus 41.8 (IQR: 18.7) counted in control livers
(P = 0.1014).
Fig. 2 hAEC treatment reduces extracellular matrix deposition. Livers extracted from control (BDL + PBS) and treated (BDL + hAEC) rats, 6 weeks
after bile duct ligation (BDL), were evaluated for extracellular matrix protein (fibronectin and collagen) deposition and the degree of fibrosis. Repre-
sentative microphotographs of fibronectin immuno-staining and collagen staining (PicroSirius Red: PSR) are reported in panels (A) and (B). hAEC-
treated rats showed lower hepatic areas, quantified by computer-assisted image analysis, positive for fibronectin (A) and PSR (B), and reduced liver
fibrosis in terms of Knodell’s score units (C). Similar results were obtained for fibronectin (D) and collagen 1A1 (E) mRNA liver expression. Scale
bars = 100 lm (A), 200 lm (B). *P < 0.05 and **P < 0.01, versus BDL + PBS group.
ª 2017 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
1207
J. Cell. Mol. Med. Vol 22, No 2, 2018
Reactive ductular cells can also indirectly promote fibroblast dif-
ferentiation towards myofibroblasts by activating latent TGF-b
through up-regulation of avb6 integrin expressed on their cell mem-
brane [11, 12]; of note in sections from healthy livers, ductular cells
did not express avb6 integrin. We explored whether hAEC treatment
reduced TGF-b pathway activation via inhibition of ductular expres-
sion of avb6 integrin. We first observed that avb6 integrin expression
was lower in livers of hAEC-treated animals [9.22 (IQR: 9.32) versus
15.75 (IQR: 4.68) % liver-positive area for avb6 integrin; P < 0.05]
(Fig. 5A). We then verified whether this effect was associated with
TGF-b pathway inhibition. To this end, we used phosphorylated Smad
2/3 (p-Smad2/3) expression as an indicator of TGF-b activation as
p-Smad2/3 proteins act as pivotal downstream effectors of TGF-b by
transferring signals from TGF-b receptors to the nucleus. In hAEC-
treated animals, in concert with the reduction in avb6 integrin
expression, we observed a strong and significant reduction in
p-Smad2/3-positive cells [2.86 (IQR: 2.07) versus 4.92 (IQR: 1.20) %
liver-positive area for p-Smad2/3; P < 0.01] (Fig. 5B).
hAEC do not act on liver sinusoidal endothelial
cell defenestration
Finally, we investigated the ability of hAEC to reduce sinusoidal ‘capil-
larization’, a process thought to be involved in liver fibrosis develop-
ment and HSC activation [13, 14]. This process results in alteration of
LSEC phenotype with loss of their ‘fenestrae’ (defenestration) and
basement membrane formation. To evaluate the effect of hAEC on
LSEC, we analysed the expression of CD32b, a cell surface protein
that correlates with the presence of cell fenestrations [27]. As
expected, BDL induced a reduction in LSEC fenestrations; in fact, liv-
ers from healthy animals showed an area positive for CD32b ranging
between 7.1 and 13.8% of the total section area, while it was reduced
to 1.6 and 3.9% in BDL animals. Our data show that hAEC did not
affect BDL-induced sinusoidal defenestration; CD32b expression was
similar in animals from both BDL + PBS and BDL + hAEC groups
[2.70 (IQR: 2.07) versus 2.93 (IQR: 1.12) % liver-positive area for
CD32b, respectively; P = 0.593] (Fig. 6A).
Fig. 3 hAEC treatment decreases hepatic fibroblast activation. Immunohistochemical and quantitative image analysis of rat liver sections from control
(BDL + PBS) and treated (BDL + hAEC) rats, 6 weeks after BDL. In hAEC-treated rats, the percentages of liver areas occupied by activated myofi-
broblasts (a-SMA-positive cells) (A), by myofibroblasts derived from portal fibroblasts (PF) (collagen 15A1-positive liver areas) (B) and by myofi-
broblasts derived from hepatic stellate cells (HSC) (desmin-positive liver areas) (C), are reduced compared to the control (BDL + PBS) group.
Similar results were obtained from the analysis of mRNA expression (panels A, B and C). Scale bars = 100 lm. *P < 0.05 and **P < 0.01 versus
BDL + PBS group.
1208 ª 2017 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
Although hAEC treatment does not affect LSEC defenestration, it
slows the number of CD34-expressing cells (Fig. 6B), which have
been shown to increase during capillarization [28].
Discussion
We and others have previously demonstrated that amniotic mem-
brane and hAEC decrease liver fibrosis in terms of reduction in myofi-
broblast levels and collagen deposition [16, 18, 19, 21]. Considering
the fundamental role of myofibroblasts in the development and pro-
gression of the fibrotic lesion, in this study, we aimed to narrow down
the actions of hAEC on different myofibroblast precursors, namely
HSC, PF, epithelial ductular cells and LSEC.
Myofibroblasts, the key fibrogenic cells responsible for ECM syn-
thesis and deposition, derive from the activation of PF and HSC, two
liver fibroblast populations with distinctive roles in the biliary fibrotic
process. PF are the first responders to liver injury caused by biliary
obstruction, and their activation is an initial event responsible for early
ECM deposition and for triggering HSC migration and activation [6].
Activated HSC are instead responsible for the fibrosis progression.
In this study, not only do we show that hAEC significantly
reduce liver myofibroblast levels, but also for the first time we
show that hAEC exert a stronger inhibition on PF activation rather
than on HSC activation, suggesting that cell treatment affects the
cells involved in the early events of the fibrotic process and
located in the portal area, which is directly affected by biliary
occlusion. In line with the more robust actions of hAEC on PF, we
A
B
D
C
Fig. 4 hAEC treatment reduces the ductular reaction and EMT. Immunohistochemical and quantitative image analysis of rat liver sections from con-
trol (BDL + PBS) and treated (BDL + hAEC) rats, 6 weeks after BDL. Livers from hAEC-treated rats exhibited a significant decrease in liver area
occupied by ductular epithelial cells (positive for CK19) (A) and a lower number of cells undergoing EMT (positive for S100A4) (B). The treatment
did not affect the number of positive cells located in parenchymal and ductular areas, but rather those close to ductular structures (periductular
cells) (C and D). Scale bars = 100 lm (A and B) and 50 lm (C). *P < 0.05 versus BDL + PBS group.
ª 2017 The Authors.
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observed a robust decrease in fibronectin levels which could be
justified by previous studies which have shown that myofibroblasts
derived from PF produce higher levels of fibronectin with respect
to myofibroblasts derived from HSC [3, 4].
We furthermore investigated the ability of hAEC to limit the pro-
fibrogenic activity of epithelial ductular cells that also participate to
myofibroblast generation.
Indeed, these cells may give rise to an early reaction (‘ductular
reaction’) characterized by a strong ductular proliferation and acquisi-
tion of an inflammatory phenotype leading to the secretion of inflam-
matory mediators promoting the activation of periductular fibroblasts
towards myofibroblasts. Our data demonstrate that hAEC strongly
decrease ductular proliferation and thus possibly contribute in reduc-
ing the inflammatory milieu generated by the reactive ductular cells
and consequently their pro-fibrogenic activity. Under BDL-induced
inflammatory conditions, avb6 integrin is up-regulated on the ductu-
lar surface [7], and it represents a key link between ductular inflam-
mation and biliary fibrotic process. This integrin is indeed directly
involved in liver fibrogenesis as it locally (in periductular areas) acti-
vates TGF-b [12, 29], the main fibrogenic factor, which, under normal
conditions is extracellularly stored in its inactive latent form unable to
bind to its receptors. The crucial role of avb6 integrin in TGF-b activa-
tion has been demonstrated in biliary fibrosis models where its
neutralization has been shown to decrease fibrosis progression [12,
30, 31].
Importantly, we observed that hAEC treatment effectively
decreases ductular expression of avb6 integrin, and this action is
associated to a significant reduction in TGF-b activation.
Interestingly, given the involvement of fibronectin in TGF-b activa-
tion mediated by avb6 integrin [29], the lower fibronectin deposition
observed in livers from hAEC-treated animals could also contribute to
maintaining TGF-b in its inactivated, bound-latent form.
Furthermore, as avb6 integrin has been shown to induce the pro-
liferation of different cells [32, 33], the inhibition of ductular avb6
expression could also contribute to the reduced proliferation of reac-
tive ductular cells.
In addition to ‘ductular reaction’, after liver injury, ductular epithe-
lial cells may undergo epithelial-to-mesenchymal transition giving ris-
ing to EMT-derived fibroblasts which potentially differentiate towards
ECM-producing myofibroblasts. We found that hAEC treatment
reduces the number of EMT-derived periductular fibroblasts
(S100A4-positive cells) [10, 26], but it remains to be clarified whether
this reduction could contribute to the decreased myofibroblast levels
observed after hAEC treatment [34].
Finally, on the basis of the ability of the amniotic membrane to
maintain liver sinusoidal cell fenestrations during in vitro culture [35],
A
B
C
Fig. 5 hAEC treatment decreases TGF-b pathway activation. Immunohistochemical and quantitative image analysis of rat liver sections from control
(BDL + PBS) and treated (BDL + hAEC) rats, 6 weeks after BDL. Representative microphotographs related to: (A) avb6 integrin ductular expression
—up-regulated under BDL conditions—and (B) phosphorylated Smad2/3 expression—identifying cells with activated TGF-b pathway. hAEC-treated
rats show a lower hepatic area occupied by avb6 integrin (A) associated with a strong reduction in p-Smad2/3-positive area (B). p-Smad2/3 signals
are located in perinuclear and nuclear areas indicating both ongoing and completed translocations of p-Smad2/3 to the nucleus (in box C, 10009
magnification). Scale bars = 100 lm (A) and 50 lm (B). *P < 0.05 and **P < 0.01 versus BDL + PBS group.
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we explored whether hAEC could retain this ability in BDL, a condition
which also induces sinusoidal loss of fenestration and ‘capillarization’.
Instead, we found that hAEC treatment does not limit sinusoidal cell
defenestration, but only appears to slow CD34 expression which has
been reported to increase during the ‘capillarization’ process [28].
The finding that hAEC do not seem to target sinusoidal cells, although
involved in the early fibrotic process, could be attributed to the fact
that these are not highly proliferating cells and thus may be less sus-
ceptible to the antiproliferative action of hAEC [36–40].
In conclusion, our data show that hAEC reduce PF activation
towards myofibroblasts and the ability of reactive ductular cells to
generate periductular myofibroblasts. Thus, our results suggest that
hAEC act on pro-fibrogenic cells located in portal area and directly
involved in biliary injury, which display an early, proliferative activity
and an inflammatory phenotype. Finally, these data suggest the appli-
cation of hAEC as a possible therapy not only in biliary-associated
fibrosis, but also in any liver injury which involves the expansion and
activation of the ductular epithelial compartment.
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